ADAM-17 Activity and Its Relation to ACE2: Implications for Severe COVID-19

Author:

Sun Jiangming1ORCID,Edsfeldt Andreas123,Svensson Joel4,Ruge Toralph567,Goncalves Isabel12,Swärd Per8ORCID

Affiliation:

1. Cardiovascular Research-Translational Studies, Department of Clinical Sciences Malmö, Lund University, 205 02 Malmö, Sweden

2. Department of Cardiology, Skåne University Hospital, 205 02 Malmö, Sweden

3. Wallenberg Center for Molecular Medicine, Lund University, 221 00 Lund, Sweden

4. Department of Laboratory Medicine, Lund University, 221 00 Lund, Sweden

5. Department of Emergency and Internal Medicine, Skånes University Hospital, 214 28 Malmö, Sweden

6. Department of Clinical Sciences Malmö, Lund University, 214 28 Malmö, Sweden

7. Department of Internal Medicine, Skåne University Hospital, 214 28 Malmö, Sweden

8. Clinical and Molecular Osteoporosis Research Unit, Departments of Orthopedics and Clinical Sciences, Skåne University Hospital, Lund University, 205 02 Malmö, Sweden

Abstract

There is a lack of studies aiming to assess cellular a disintegrin and metalloproteinase-17 (ADAM-17) activity in COVID-19 patients and the eventual associations with the shedding of membrane-bound angiotensin-converting enzyme 2 (mACE2). In addition, studies that investigate the relationship between ACE2 and ADAM-17 gene expressions in organs infected by SARS-CoV-2 are lacking. We used data from the Massachusetts general hospital COVID-19 study (306 COVID-19 patients and 78 symptomatic controls) to investigate the association between plasma levels of 33 different ADAM-17 substrates and COVID-19 severity and mortality. As a surrogate of cellular ADAM-17 activity, an ADAM-17 substrate score was calculated. The associations between soluble ACE2 (sACE2) and the ADAM-17 substrate score, renin, key inflammatory markers, and lung injury markers were investigated. Furthermore, we used data from the Genotype-Tissue Expression (GTEx) database to evaluate ADAM-17 and ACE2 gene expressions by age and sex in ages between 20–80 years. We found that increased ADAM-17 activity, as estimated by the ADAM-17 substrates score, was associated with COVID-19 severity (p = 0.001). ADAM-17 activity was also associated with increased mortality but did not reach statistical significance (p = 0.06). Soluble ACE2 showed the strongest positive correlation with the ADAM-17 substrate score, follow by renin, interleukin-6, and lung injury biomarkers. The ratio of ADAM-17 to ACE2 gene expression was highest in the lung. This study indicates that increased ADAM-17 activity is associated with severe COVID-19. Our findings also indicate that there may a bidirectional relationship between membrane-bound ACE2 shedding via increased ADAM-17 activity, dysregulated renin–angiotensin system (RAS) and immune signaling. Additionally, differences in ACE2 and ADAM-17 gene expressions between different tissues may be of importance in explaining why the lung is the organ most severely affected by COVID-19, but this requires further evaluation in prospective studies.

Funder

Kockska foundation

Swedish Research Council

Swedish Heart and Lung Foundation

Swedish Society for Medical Research

Swedish Society of Medicine

Emil and Wera Cornell foundation

ALF Grants Region Skåne

Crawfoord foundation

Diabetes foundation

SUS funds

Stroke foundation

Swedish Stroke Association

Albert Påhlsson’s foundation

Swedish Foundation for Strategic Research

Knut and Alice Wallenberg foundation

Medical Faculty at Lund University and Region Skåne

Publisher

MDPI AG

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3